Global Molecular Infectious Disease Testing Market Size study & Forecast, by Product (Instruments, Reagents), Technology (Mass Spectrometry, PCR, In Situ Hybridization), Application, End-use and Regional Forecasts 2025-2035

Description

The Global Molecular Infectious Disease Testing Market, valued at approximately USD 16.2 billion in 2024, is projected to expand at a steady CAGR of around 3.40% during the forecast period from 2025 to 2035, ultimately reaching about USD 23.40 billion by the end of the period. Molecular infectious disease testing, a cornerstone of modern diagnostics, has transformed the way clinicians identify, monitor, and manage infectious agents with unmatched precision and speed. Leveraging advanced molecular technologies, these tests detect specific genetic material from pathogens, enabling early detection and targeted treatment plans. The market's growth trajectory is being fueled by the persistent burden of infectious diseases, the heightened global awareness following recent pandemic events, and the increasing integration of molecular diagnostics in routine healthcare settings. Additionally, rapid advancements in assay design, automated workflows, and point-of-care molecular systems are enhancing operational efficiency and reducing turnaround times for critical diagnoses.

An upsurge in demand for reliable and high-throughput testing solutions is further catalyzing market expansion, as healthcare providers aim to curb outbreaks and improve patient outcomes. The adoption of molecular diagnostics in decentralized healthcare environments-ranging from outpatient clinics to home-based testing-has opened new revenue streams for industry stakeholders. According to industry insights, the continued prevalence of healthcare-associated infections and emerging antimicrobial resistance patterns has compelled laboratories to adopt molecular platforms capable of multiplex detection and antimicrobial resistance profiling. Moreover, the integration of artificial intelligence and big data analytics into molecular testing workflows is revolutionizing result interpretation, paving the way for predictive epidemiology and more efficient public health interventions. However, cost-intensive instrumentation, the need for skilled laboratory personnel, and disparities in diagnostic infrastructure across emerging economies continue to present challenges to market penetration.

From a regional perspective, North America held the dominant share of the market in 2024, benefiting from robust healthcare infrastructure, widespread adoption of cutting-edge diagnostic tools, and strong funding for infectious disease surveillance. The United States, with its well-established network of clinical laboratories and public health agencies, remains a key driver of innovation and adoption in this sector. Europe follows closely, propelled by rising investments in genomic medicine, regulatory support for rapid diagnostic deployment, and heightened vigilance against cross-border disease transmission. The Asia Pacific region is anticipated to witness the fastest growth through 2035, fueled by a surging patient base, government-led healthcare modernization programs, and increased private sector investment in diagnostic capabilities. Countries like China and India are rapidly scaling up their molecular testing capacities to meet the demands of urbanization, globalization, and shifting disease epidemiology. Meanwhile, Latin America and the Middle East & Africa are gradually strengthening their diagnostic ecosystems through collaborative initiatives and donor-funded projects aimed at bolstering infectious disease control programs.

Major market player included in this report are:

Abbott Laboratories
Thermo Fisher Scientific Inc.
Becton, Dickinson and Company
F. Hoffmann-La Roche Ltd.
Danaher Corporation
Qiagen N.V.
Hologic, Inc.
bioMerieux SA
Illumina, Inc.
Bio-Rad Laboratories, Inc.
Siemens Healthineers AG
GenMark Diagnostics, Inc.
Agilent Technologies, Inc.
Luminex Corporation
Cepheid (a Danaher Company)

Global Molecular Infectious Disease Testing Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Product:

Instruments
Reagents

By Technology:

Mass Spectrometry
PCR
In Situ Hybridization

By Application:

[Application-specific segmentation to be detailed based on market data]

By End-use:

[End-use-specific segmentation to be detailed based on market data]

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Molecular Infectious Disease Testing Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study (Historical Data - 2023, 2024; Base Year for Estimation - 2024; Forecast period - 2025-2035)

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Key Findings

Chapter 3. Global Molecular Infectious Disease Testing Market Forces Analysis

3.1. Market Forces Shaping The Global Molecular Infectious Disease Testing Market (2024-2035)
3.2. Drivers
- 3.2.1. Persistent burden of infectious diseases and heightened surveillance post-pandemic
- 3.2.2. Rising adoption of molecular diagnostics (PCR, multiplex assays) across clinical settings
- 3.2.3. Increasing demand for rapid, high-throughput and point-of-care testing solutions
- 3.2.4. Growing emphasis on antimicrobial resistance profiling and precision public health
3.3. Restraints
- 3.3.1. High capital expenditure for instrumentation and cost per test constraints
- 3.3.2. Limited skilled laboratory personnel and technical expertise in emerging markets
- 3.3.3. Regulatory complexities, reimbursement challenges and variability in market access
3.4. Opportunities
- 3.4.1 Expansion of multiplex assays and syndromic panels for respiratory and bloodstream infections
- 3.4.2 Decentralization via POC molecular platforms and home-based testing models
- 3.4.3 Integration of AI/big data for result interpretation and epidemiological forecasting
- 3.4.4 Market penetration in Asia Pacific, Latin America and Africa through capacity building initiatives

Chapter 4. Global Molecular Infectious Disease Testing Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Molecular Infectious Disease Testing Market Size & Forecasts by Product & Technology 2025-2035

5.1. Market Overview
5.2. Global Molecular Infectious Disease Testing Market Performance - Potential Analysis (2025)
5.3. Instruments
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. Reagents
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035
5.5. Mass Spectrometry (Technology)
- 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.5.2. Market size analysis, by region, 2025-2035
5.6. PCR (Technology)
- 5.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.6.2. Market size analysis, by region, 2025-2035
5.7. In Situ Hybridization (Technology)
- 5.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.7.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Molecular Infectious Disease Testing Market Size & Forecasts by Application 2025-2035

6.1. Market Overview
6.2. Global Molecular Infectious Disease Testing Market Performance - Potential Analysis (2025)
6.3. Respiratory Infections (e.g., SARS, Influenza)
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Bloodstream Infections / Sepsis
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
6.5. Sexually Transmitted Infections
- 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.5.2. Market size analysis, by region, 2025-2035
6.6. Gastrointestinal & Other Applications
- 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.6.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Molecular Infectious Disease Testing Market Size & Forecasts by Region 2025-2035

7.1. Molecular Infectious Disease Testing Market, Regional Market Snapshot
7.2. Top Leading & Emerging Countries
7.3. North America Molecular Infectious Disease Testing Market
- 7.3.1. U.S. Molecular Infectious Disease Testing Market
  - 7.3.1.1. Product (Instruments, Reagents) breakdown size & forecasts, 2025-2035
  - 7.3.1.2. Technology (Mass Spec, PCR, ISH) breakdown size & forecasts, 2025-2035
- 7.3.2. Canada Molecular Infectious Disease Testing Market
  - 7.3.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.3.2.2. Technology breakdown size & forecasts, 2025-2035
7.4. Europe Molecular Infectious Disease Testing Market
- 7.4.1. UK Molecular Infectious Disease Testing Market
  - 7.4.1.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.1.2. Technology breakdown size & forecasts, 2025-2035
- 7.4.2. Germany Molecular Infectious Disease Testing Market
  - 7.4.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.2.2. Technology breakdown size & forecasts, 2025-2035
- 7.4.3. France Molecular Infectious Disease Testing Market
  - 7.4.3.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.3.2. Technology breakdown size & forecasts, 2025-2035
- 7.4.4. Spain Molecular Infectious Disease Testing Market
  - 7.4.4.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.4.2. Technology breakdown size & forecasts, 2025-2035
- 7.4.5. Italy Molecular Infectious Disease Testing Market
  - 7.4.5.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.5.2. Technology breakdown size & forecasts, 2025-2035
- 7.4.6. Rest of Europe Molecular Infectious Disease Testing Market
  - 7.4.6.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.6.2. Technology breakdown size & forecasts, 2025-2035
7.5. Asia Pacific Molecular Infectious Disease Testing Market
- 7.5.1. China Molecular Infectious Disease Testing Market
  - 7.5.1.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.1.2. Technology breakdown size & forecasts, 2025-2035
- 7.5.2. India Molecular Infectious Disease Testing Market
  - 7.5.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.2.2. Technology breakdown size & forecasts, 2025-2035
- 7.5.3. Japan Molecular Infectious Disease Testing Market
  - 7.5.3.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.3.2. Technology breakdown size & forecasts, 2025-2035
- 7.5.4. Australia Molecular Infectious Disease Testing Market
  - 7.5.4.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.4.2. Technology breakdown size & forecasts, 2025-2035
- 7.5.5. South Korea Molecular Infectious Disease Testing Market
  - 7.5.5.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.5.2. Technology breakdown size & forecasts, 2025-2035
- 7.5.6. Rest of APAC Molecular Infectious Disease Testing Market
  - 7.5.6.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.6.2. Technology breakdown size & forecasts, 2025-2035
7.6. Latin America Molecular Infectious Disease Testing Market
- 7.6.1. Brazil Molecular Infectious Disease Testing Market
  - 7.6.1.1. Product breakdown size & forecasts, 2025-2035
  - 7.6.1.2. Technology breakdown size & forecasts, 2025-2035
- 7.6.2. Mexico Molecular Infectious Disease Testing Market
  - 7.6.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.6.2.2. Technology breakdown size & forecasts, 2025-2035
7.7. Middle East and Africa Molecular Infectious Disease Testing Market
- 7.7.1. UAE Molecular Infectious Disease Testing Market
  - 7.7.1.1. Product breakdown size & forecasts, 2025-2035
  - 7.7.1.2. Technology breakdown size & forecasts, 2025-2035
- 7.7.2. Saudi Arabia (KSA) Molecular Infectious Disease Testing Market
  - 7.7.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.7.2.2. Technology breakdown size & forecasts, 2025-2035
- 7.7.3. South Africa Molecular Infectious Disease Testing Market
  - 7.7.3.1. Product breakdown size & forecasts, 2025-2035
  - 7.7.3.2. Technology breakdown size & forecasts, 2025-2035

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies
8.2. Abbott Laboratories
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Financial Performance (Subject to Data Availability)
- 8.2.5. Product/Services Port
- 8.2.6. Recent Development
- 8.2.7. Market Strategies
- 8.2.8. SWOT Analysis
8.3. Thermo Fisher Scientific Inc.
8.4. Becton, Dickinson and Company (BD)
8.5. F. Hoffmann-La Roche Ltd.
8.6. Danaher Corporation
8.7. Qiagen N.V.
8.8. Hologic, Inc.
8.9. bioMerieux SA
8.10. Illumina, Inc.
8.11. Bio-Rad Laboratories, Inc.
8.12. Siemens Healthineers AG
8.13. GenMark Diagnostics, Inc.
8.14. Agilent Technologies, Inc.
8.15. Luminex Corporation
8.16. Cepheid (a Danaher Company)